Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05573035 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate LYL845 in Adults With Solid Tumors
A Phase 1 study, sponsored by Lyell Immunopharma.
- Terminated
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
NCT05573035: Clinical Trial Phase 1 study, sponsored by Lyell Immunopharma.
NCT05573035 is a Phase 1 study that was terminated before completion, run by Lyell Immunopharma. The registered enrollment target is 39 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (35% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05573035, a Phase 1 study, was terminated before completion, sponsored by Lyell Immunopharma.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
This is an open-label, multi-center, dose-escalation study with expansion cohorts, designed to evaluate the safety and anti-tumor activity of LYL845, an epigenetically reprogrammed tumor infiltrating lymphocyte (TIL) therapy, in participants with relapsed or refractory (R/R) metastatic or locally advanced melanoma, non-small cell lung cancer (NSCLC), and colorectal cancer (CRC).
Primary Outcome
Evaluate incidence of dose-limiting toxicities (DLTs)
Interventions
- BIOLOGICAL LYL845
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2022-12-19 |
| Est. Completion | 2025-01-09 |
| Phase | Phase 1 |
Why NCT05573035 stopped before completion
NCT05573035 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (35% lower).
The record links to 0 conditions, and to 1 intervention - of which LYL845 is the first listed.
NCT05573035 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05573035 about?
NCT05573035 is a clinical study titled "A Study to Investigate LYL845 in Adults With Solid Tumors". This is an open-label, multi-center, dose-escalation study with expansion cohorts, designed to evaluate the safety and anti-tumor activity of LYL845, an epigenetically reprogrammed tumor infiltrating lymphocyte (TIL) therapy, in participants with relapsed or refractory (R/R) metastatic or locally ad...
What is the current status of trial NCT05573035?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2022-12-19. Estimated completion is 2025-01-09.
What interventions are being tested in trial NCT05573035?
The interventions under investigation include: LYL845 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05573035?
This trial is sponsored by Lyell Immunopharma, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05573035's enrollment target sits among peer trials
39 1191st of 2000 higher than 804 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI